ArticleDrug design, development and therapy2026
Targeted Comprehensive Screening of Neuropsychiatric Drugs in Serum by LC-MS/MS: Method Development and Three-Year Clinical Utility.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The increasing prevalence of neuropsychiatric medication misuse highlights the critical need for efficient drug screening in clinical laboratories. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) application for broad serum drug screening remains limited in many clinical settings. Serum analysis is particularly valuable for identifying current drug exposure, confirming the cause of intoxication, and monitoring patient medication adherence. Purpose: This study aimed to develop and validate an LC-MS/MS method using multiple reaction monitoring followed by information-dependent acquisition-triggered enhanced product ion scans for the simultaneous qualitative identification of 77 neuropsychiatric drugs, and to present its large-scale clinical application over three years. Methods: Validation included precision, accuracy, recovery, matrix effects, selectivity, and interference. A minimal serum volume (20 μL) underwent simple protein precipitation, with preparation time under 15 minutes per batch. This method was applied to 1,021 clinical serum specimens. Results: Chromatographic separation was completed in 15 minutes. The precisions (CV) for calculated concentrations and retention times were < 30% and < 1.5%, respectively. Accuracy was assessed for 60 of the 77 analytes (100% agreement). Mean recovery and matrix effects were 93.1% and 99.9%, respectively. Most test orders originated from psychiatry and neurology outpatients. Although fewer orders came from the Department of Emergency Medicine (EM), the EM patients exhibited a higher positivity rate. The most frequently detected drug classes were benzodiazepines (37.9%), antidepressants (30.7%), and antipsychotics (19.7%). Common specific analytes included clonazepam/7-aminoclonazepam (10.2%) and lorazepam (10.0%). Conclusion: We developed and validated a LC-MS/MS method for the simultaneous detection of a wide range of neuropsychiatric drugs. The method proved essential for verifying medication history, identifying non-adherence, and diagnosing acute intoxication. Our findings highlight the critical role of broad-spectrum serum screening in managing medication-related emergencies and optimizing long-term therapeutic care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.